Isabelle Bedrosian, M.D., F.A.C.S.

Peer-Reviewed Articles

1. Simons JM, Scoggins ME, Kuerer HM, Krishnamurthy S, Yang WT, Sahin AA, Shen Y, Lin H, Bedrosian I, Mittendorf EA, Thompson A, Lane DL, Hunt KK, Caudle AS. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol 28(8):4277-4283, 2021. e-Pub 2021. PMID: 33417121.
2. Wood ME, Liu H, Storrick E, Zahrieh D, Le-Petross HC, Jung SH, Zekan P, Kemeny MM, Charlamb JR, Wang LX, Unzeitig GW, Johnson CS, Garber JE, Marshall JR, Bedrosian I. The influence of vitamin D on mammographic density: results from CALGB 70806 (Alliance) a randomized clinical trial. Cancer Prev Res (Phila) 14(7):753-762, 2021. e-Pub 2021. PMID: 33849913.
3. Tamirisa N, Lin H, Shen Y, Shaitelman SF, Karuturi MS, Giordano SH, Babiera GV, Bedrosian I. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-a National Cancer Database analysis. Cancer 127(13):2196-2203, 2021. e-Pub 2021. PMID: 33735487.
4. Bhardwaj A, Embury MD, Rojo RD, Albarracin C, Bedrosian I. Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer. Breast Cancer Res Treat 187(2):363-374, 2021. e-Pub 2021. PMID: 33893908.
5. Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Ann Oncol 32(5):642-651, 2021. e-Pub 2021. PMID: 33617937.
6. McLemore LE, Albarracin CT, Gruschkus SK, Bassett RL, Wu Y, Dhamne S, Yim I, Lin K, Bedrosian I, Sneige N, Chen H. HER2 Testing in Breast Cancers: Comparison of Assays and Interpretation Using ASCO/CAP 2013 and 2018 Guidelines. Breast Cancer Res Treat 187(1):95-104, 2021. e-Pub 2021. PMID: 33813685.
7. Baughan NM, Li H, Lan L, Chan C, Embury M, Whitman G, El-Zein R, Bedrosian I, Giger M. Parenchymal field effect analysis for breast cancer risk assessment: evaluation of FFDM radiomic similarity. SPIE. Digital Library, 2021. e-Pub 2021.
8. Yang L, Roy M, Lin H, Shen Y, Albarracin C, Huo L, Wei B, Bedrosian I, Bu H, Wu Y. Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast. Breast Cancer Research and Treatment, 2021. e-Pub 2021.
9. Murphy BL, Yi M, Arun BK, Gutierrez Barrera AM, Bedrosian I. Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing. Ann Surg Oncol 27(12):4613-4621, 2020. e-Pub 2020. PMID: 32720048.
10. Napoli M, Li X, Ackerman H, Deshpande A, Barannikov I, Pisegna M, Bedrosian I, Mitsch J, Quinlan P, Thompson A, Rajapakshe K, Coarfa C, Gunaratne P, Marchion D, Magliocco A, Tsai K, Flores E. Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs (TROLLs) that promote cancer progression through AKT activation. Nature, 2020.
11. Lau R, Du L, Chen E, Fu C, Gould R, Marczyk M, Sinn BV, Layman R, Bedrosian I, Valero V, Symmans WF. Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. Clin Chem. e-Pub 2020. PMID: 32613237.
12. Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Woodward WA, Ueno NT, Lucci A. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Ann Surg Oncol. e-Pub 2020. PMID: 32710271.
13. Murphy BL, Bedrosian I. ASO Author Reflections: Performance of Contralateral Risk-Reducing Mastectomy in Multigene Panel-Tested Patients is High in All Types of Germline Mutation Carriers. Ann Surg Oncol. e-Pub 2020. PMID: 32712892.
14. Tamirisa N, Lin H, Shen Y, Shaitelman SF, Sri Karuturi M, Giordano SH, Babiera G, Bedrosian I. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. JAMA Oncol. e-Pub 2020. PMID: 32672820.
15. Kuhl CK, Lehman C, Bedrosian I. Imaging in Locoregional Management of Breast Cancer. J Clin Oncol:JCO1903257, 2020. e-Pub 2020. PMID: 32442068.
16. Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol:JCO2000299. e-Pub 2020. PMID: 32243226.
17. Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). J Clin Oncol 38(12):1284-1292, 2020. e-Pub 2020. PMID: 32125937.
18. Ju Z, Bhardwaj A, Embury MD, Singh H, Gunaratne PH, Bedrosian I, Wang J. Integrative Analyses of Multilevel Omics Reveal Preneoplastic Breast to Possess a Molecular Landscape That is Globally Shared with Invasive Basal-Like Breast Cancer (Running Title: Molecular Landscape of Basal-Like Breast Cancer Progression). Cancers (Basel) 12(3), 2020. e-Pub 2020. PMID: 32204397.
19. Yi M, Lin H, Bedrosian I, Shen Y, Hunt KK, Chavez-MacGregor M, King TA, Mittendorf EA. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. Ann Surg Oncol 27(2):359-366, 2020. e-Pub 2019. PMID: 31667721.
20. Park KU, Kyrish K, Yi M, Bedrosian I, Caudle AS, Kuerer HM, Hunt KK, Miggins MV, DeSnyder SM. Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. Ann Surg Oncol. e-Pub 2019. PMID: 31820211.
21. Raber BM, Lin H, Shen Y, Shaitelman SF, Bedrosian I. Trends in Regional Nodal Management of Breast Cancer Patients with Low Nodal Burden. Ann Surg Oncol. e-Pub 2019. PMID: 31605340.
22. Buszek SM, Lin HY, Bedrosian I, Tamirisa N, Babiera GV, Shen Y, Shaitelman SF. Lumpectomy plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older with Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database. Int J Radiat Oncol Biol Phys. e-Pub 2019. PMID: 31377160.
23. Weiss A, Lin H, Babiera GV, Bedrosian I, Shaitelman SF, Shen Y, Kuerer HM, Mittendorf EA, Caudle AS, Hunt KK, Hwang RF. Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. Breast Cancer Res Treat 176(2):435-444, 2019. e-Pub 2019. PMID: 31025270.
24. Park KU, Kyrish K, Terrell J, Yi M, Caudle AS, Hunt KK, Kuerer HM, Bedrosian I, Thompson A, DeSnyder SM, other members of Department of Breast Surgical Oncology Study Group. Surgeon perception versus reality: Opioid use after breast cancer surgery. J Surg Oncol 119(7):909-915, 2019. e-Pub 2019. PMID: 30737785.
25. Tevis SE, Bassett R, Bedrosian I, Barcenas CH, Black DM, Caudle AS, DeSnyder SM, Fitzsullivan E, Hunt KK, Kuerer HM, Lucci A, Meric-Bernstam F, Mittendorf EA, Park K, Teshome M, Thompson AM, Hwang RF. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. Ann Surg Oncol 26(3):815-820, 2019. e-Pub 2018. PMID: 30556120.
26. Stecklein SR, Shaitelman SF, Babiera GV, Bedrosian I, Black DM, Ballo MT, Arzu I, Strom EA, Reed VK, Dvorak T, Smith BD, Woodward WA, Hoffman KE, Schlembach PJ, Kirsner SM, Nelson CL, Yang J, Guerra W, Dibaj S, Bloom ES. Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation with Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. Pract Radiat Oncol, 2019. e-Pub 2018. PMID: 30125673.
27. D'Agostino TA, Brewster AM, Peterson SK, Bedrosian I, Parker PA. Discussions about contralateral prophylactic mastectomy among surgical oncology providers and women with sporadic breast cancer: a content analysis. Transl Behav Med. e-Pub 2018. PMID: 30561744.
28. DeSnyder SM, Kheirkhah P, Travis ML, Lilly SE, Bedrosian I, Buchholz TA, Schaverien MV, Shaitelman SF. Optimizing Patient Positioning to Reduce Variation in the Measurement of Breast Cancer-Related Lymphedema. Lymphat Res Biol. e-Pub 2018. PMID: 30562149.
29. Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple-negative breast cancer. Breast Cancer Res 20(1):150, 2018. e-Pub 2018. PMID: 30537987.
30. Tevis SE, Neuman HB, Mittendorf EA, Kuerer HM, Bedrosian I, DeSnyder SM, Thompson AM, Black DM, Scoggins ME, Sahin AA, Hunt KK, Caudle AS. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol 25(10):2932-2938, 2018. e-Pub 2018. PMID: 29947001.
31. Weiss A, Chu CK, Lin H, Shen Y, Shaitelman SF, Garvey PB, Bedrosian I, Babiera GV. Reconstruction in the Metastatic Breast Cancer Patient: Results from the National Cancer Database. Ann Surg Oncol 25(11):3125-3133, 2018. e-Pub 2018. PMID: 30109538.
32. Parker PA, Peterson SK, Shen Y, Bedrosian I, Black DM, Thompson AM, Nelson JC, DeSnyder SM, Cook RL, Hunt KK, Volk RJ, Cantor SB, Dong W, Brewster AM. Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. J Clin Oncol 36(25):2630-2638, 2018. e-Pub 2018. PMID: 30044695.
33. Elsayegh N, Webster RD, Gutierrez A, Lin H, Kuerer HM, Litton J, Bedrosian I, Arun B. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Medicine, 2018.
34. Weiss A, Menen RS, Lin HY, Shen Y, Rosso KJ, Shaitelman S, Woodward W, Valero V, Ueno NT, Bedrosian I, Babiera G. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Res Treat. e-Pub 2018. PMID: 29460033.
35. Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. e-Pub 2017. PMID: 29100726.
36. Caudle AS, Bedrosian I, Milton DR, DeSnyder SM, Kuerer HM, Hunt KK, Mittendorf EA. Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol. e-Pub 2017. PMID: 28766207.
37. Moreno AC, Lin YH, Bedrosian I, Shen Y, Stauder MC, Smith BD, Buchholz TA, Babiera GV, Woodward WA, Shaitelman SF. Use of regional nodal irradiation and its association with survival for women with high-risk, early stage breast cancer: A National Cancer Database analysis. Adv Radiat Oncol 2(3):291-300, 2017. e-Pub 2017. PMID: 29114595.
38. Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. e-Pub 2017. PMID: 28608612.
39. Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH. Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123(11):1935-1940, 2017. e-Pub 2017. PMID: 28135395.
40. Yao K, Belkora J, Bedrosian I, Rosenberg S, Sisco M, Barrera E, Kyrillos A, Tilburt J, Wang C, Rabbitt S, Pesce C, Simovic S, Winchester DJ, Sepucha K. Erratum to: Impact of an In-visit Decision Aid on Patient Knowledge about Contralateral Prophylactic Mastectomy: A Pilot Study. Ann Surg Oncol. e-Pub 2017. PMID: 28349337.
41. Lin HY, Bedrosian I, Babiera GV, Shaitelman SF, Kuerer HM, Woodward WA, Ueno NT, Shen Y. Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer. e-Pub 2017. PMID: 28295213.
42. FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, Caudle AS, Black DM, Bedrosian I, Reyna C, Teshome M, Meric-Bernstam F, Hwang R. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol 24(3):652-659, 2017. e-Pub 2016. PMID: 27822630.
43. Bhardwaj A, Singh H, Rajapakshe K, Tachibana K, Ganesan N, Pan Y, Gunaratne PH, Coarfa C, Bedrosian I. Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple negative breast cancer. Oncotarget 8(12):19645-19660, 2017. e-Pub 2017. PMID: 28160548.
44. Mitchell KB, Lin H, Shen Y, Colfry A, Kuerer H, Shaitelman SF, Babiera GV, Bedrosian I. DCIS and AXillary Nodal Evaluation: Compliance with National Guidelines. BMC Surg 17(1):12, 2017. e-Pub 2017. PMID: 28173790.
45. Yao K, Belkora J, Bedrosian I, Rosenberg S, Sisco M, Barrera E, Kyrillios A, Tilburt J, Wang C, Rabbitt S, Pesce C, Simovic S, Winchester DJ, Sepucha K. Impact of an In-visit Decision Aid on Patient Knowledge about Contralateral Prophylactic Mastectomy: A Pilot Study. Ann Surg Oncol 24(1):91-99, 2017. e-Pub 2016. PMID: 27654108.
46. Menen RS, Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I. Long-term safety of observation in selected women following core biopsy diagnosis of atypical ductal hyperplasia. Ann Surg Oncol 24(1):70-76, 2017. e-Pub 2016. PMID: 27573525.
47. Carter SA, Lyons GR, Kuerer HM, Bassett RL, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Ann Surg Oncol 23(10):3190-8, 2016. e-Pub 2016. PMID: 27406093.
48. Davies KR, Brewster AM, Bedrosian I, Parker PA, Crosby MA, Peterson SK, Shen Y, Volk RJ, Cantor SB. Outcomes of Contralateral Prophylactic Mastectomy in Relation to Familial History: A Decision Analysis (BRCR-D-16-00033). Breast Cancer Res 18(1):93, 2016. e-Pub 2016. PMID: 27650678.
49. Loveland-Jones C, Lin H, Shen Y, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno N, Valero V, Babiera G. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys 95(4):1218-25, 2016. e-Pub 2016. PMID: 27209502.
50. Yao K, Belkora J, Sisco M, Rosenberg S, Bedrosian I, Liederbach E, Wang C. Surgeon Deficits in Knowledge of Contralateral Prophylactic Mastectomy: A Survey. JAMA Surg 151(4):1-3, 2016. e-Pub 2015. PMID: 26606424.
51. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol 34(10):1072-8, 2016. e-Pub 2016. PMID: 26811528.
52. Nakhlis F, Gilmore L, Gelman R, Bedrosian I, Ludwig K, Hwang ES, Willey S, Hudis C, Iglehart JD, Lawler E, Ryabin NY, Golshan M, Schnitt SJ, King TA. The incidence of adjacent synchronous invasive carcinoma and/or DCIS in patients with lobular neoplasia on core biopsy: results from a prospective multi-institutional registry (TBCRC 020). Ann Surg Oncol 23(3):722-8, 2016. e-Pub 2015. PMID: 26542585.
53. Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EA. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Ann Surg Oncol 23(3):749-56, 2016. e-Pub 2015. PMID: 26511263.
54. Shaitelman SF, Lin HY, Smith BD, Shen Y, Bedrosian I, Marsh GD, Bloom ES, Vicini FA, Buchholz TA, Babiera GV. Practical Implications of the Publication of Consensus Guidelines by the American Society for Radiation Oncology: Accelerated Partial Breast Irradiation and the National Cancer Data Base. Int J Radiat Oncol Biol Phys 94(2):338-48, 2016. e-Pub 2015. PMID: 26853342.
55. Moreno AC, Lin H, Bedrosian I, Shen Y, Stauder MC, Smith BD, Buchholz TA, Babiera GV, Woodward WA, Shaitelman S. Effect of Regional Nodal Irradiation on Overall Survival in Patients with High-risk Invasive Breast Cancer: A National Cancer Data Base Analysis. International Journal of Radiation Oncology • Biology • Physics 96(2):E50-51, 2016. e-Pub 2016.
56. Benveniste AP,Dryden MJ, Bedrosian I, Morrow PK, Bassett Jr. RL, Yang W. Surveillance of Women with a Personal History of Breast Cancer by Tumor Subtype. Clinical Radiology 72(3):266.e1-266.e6, 2016. PMID: 28341031.
57. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One 11(3):e0151121, 2016. e-Pub 2016. PMID: 26953790.
58. Bedrosian I, Xing Y, Abdel Rahman S, Allen L, Le-Petross H, Whitman GJ, Meric-Bernstam F, Hunt KK, Babiera GV, Cormier JN. A cost of analysis of preoperative breast MRI utilization in patients with invasive lobular cancer. Ann Surg Oncol 23(1):23-9, 2016. e-Pub 2015. PMID: 26156655.
59. Parker PA, Peterson SK, Bedrosian I, Crosby MA, Shen Y, Black DM, Babiera G, Kuerer HM, Ying J, Dong W, Cantor SB, Brewster AM. Prospective study of surgical decision-making processes for contralateral prophylactic mastectomy in women with breast cancer. Ann Surg 263(1):178-83, 2016. e-Pub 2015. PMID: 25822675.
60. Francis AM, Haugen CE, Grimes LM, Crow JR, Yi M, Mittendorf EA, Bedrosian I, Caudle AS, Babiera GV, Krishnamurthy S, Kuerer HM, Hunt KK. Is Sentinel Lymph Node Dissection Warranted in Patients with Diagnosis of Ductal Carcinoma in Situ?. Ann Surg Oncol 22(13):4270-9, 2015. e-Pub 2015. PMID: 25905585.
61. Mittendorf EA, Bedrosian I, Hunt KK. Reply to L. Antolini et al. J Clin Oncol 33(33):3978-9, 2015. e-Pub 2015. PMID: 26282647.
62. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High Incidence of Germline BRCA Mutation in Patients with ER low-positive/PR negative/HER-2 negative Breast Cancer. Cancer 121(19):3422-7, 2015. e-Pub 2015. PMID: 26280679.
63. Angelos P, Bedrosian I, Euhus DM, Herrmann VM, Katz SJ, Pusic A. Contralateral Prophylactic Mastectomy: Challenging Considerations for the Surgeon. Ann Surg Oncol 22(10):3208-12, 2015. e-Pub 2015. PMID: 26259752.
64. Lautner M, Lin H, Shen Y, Parker C, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Disparities in utilization of breast conserving therapy among early stage breast cancer patients. JAMA Surg 150(8):778-86, 2015. e-Pub 2015. PMID: 26083835.
65. Mittendorf EA, Ballman KV, McCall LM, Yi M, Sahin AA, Bedrosian I, Hansen N, Gabram S, Hurd T, Giuliano AE, Hunt KK. Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer. J Clin Oncol 33(10):1119-27, 2015. e-Pub 2014. PMID: 25488970.
66. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One 10(9):e0136851, 2015. e-Pub 2015. PMID: 26325287.
67. Bhardwaj A, Ganesan N, Tachibana K, Rajapakshe K, Albarracin CT, Gunaratne PH, Coarfa C, Bedrosian I. Annexin A1 preferentially predicts poor prognosis of basal-like breast cancer patients by activating mTOR-S6 signaling. PLoS One 10(5):e0127678, 2015. e-Pub 2015. PMID: 26000884.
68. Caudle AS, Kuerer HM, Le-Petross HT, Yang W, Yi M, Bedrosian I, Krishnamurthy S, Fornage BD, Hunt KK, Mittendorf EA. Predicting the Extent of Nodal Disease in Early-Stage Breast Cancer. Ann Surg Oncol 21(11):3440-7, 2014. e-Pub 2014. PMID: 24859939.
69. Deshmukh AA, Cantor SB, Crosby MA, Dong W, Shen Y, Bedrosian I, Peterson SK, Parker PA, Brewster AM. Cost of Contralateral Prophylactic Mastectomy. Ann Surg Oncol 21(9):2823-30, 2014. e-Pub 2014. PMID: 24809301.
70. Karhade M, Hall C, Mishra P, Anderson A, Kuerer H, Bedrosian I, Krishnamurthy S, Lucci A. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat 147(2):325-33, 2014. e-Pub 2014. PMID: 25164970.
71. Haynes AB, Bloom ES, Bedrosian I, Kuerer HM, Hwang RF, Munsell MF, Chemaly RF, Graviss LS, Caudle AS, Hunt KK, Tereffe W, Shaitelman SF, Babiera GV. Timing of infectious complications following breast-conserving therapy with catheter-based accelerated partial breast irradiation. Ann Surg Oncol 21(8):2512-6, 2014. e-Pub 2014. PMID: 24736987.
72. Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the American College of Surgeons Oncology Group Z1071 Trial Data in Clinical Practice: Is There a Way forward for Sentinel Lymph Node Dissection in Clinically Node-Positive Breast Cancer Patients treated with Neoadjuvant Chemotherapy?. Ann Surg Oncol 21(8):2468-73, 2014. e-Pub 2014. PMID: 24841348.
73. Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the national cancer database. J Clin Oncol 32(19):2018-24, 2014. e-Pub 2014. PMID: 24888808.
74. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of Biospecimen variables on Proteomic biomarkers in breast cancer. Clin Cancer Res 20(14):3870-83, 2014. e-Pub 2014. PMID: 24895461.
75. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary Tumor Resection as a Component of Multimodality Treatment May Improve Local Control and Survival in Stage IV Inflammatory Breast Cancer. Cancer 120(9):1319-28, 2014. e-Pub 2014. PMID: 24510381.
76. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 5(5):1004-11, 2014. e-Pub 2014. PMID: 24562447.
77. Advani PS, Ying J, Theriault R, Melhem-Bertrand A, Moulder S, Bedrosian I, Tereffe W, Black S, Pini TM, Brewster AM. Ethnic disparities in adherence to breast cancer survivorship surveillance care. Cancer 120(6):894-900, 2014. e-Pub 2013. PMID: 24258799.
78. Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I. Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis. PLoS One 9(5):e97076, 2014. e-Pub 2014. PMID: 24811059.
79. Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, Mittendorf EA, Babiera GV, Black DM, Wagner JL, Bedrosian I, Woodward W, Gainer SM, Hwang R, Meric-Bernstam F, Hunt KK, Kuerer HM. Incidence and Consequence of Close Margins in Patients with Ductal Carcinoma in Situ Treated with Mastectomy: Is Further Therapy Warranted?. Ann Surg Oncol 20(13):4103-12, 2013. e-Pub 2013. PMID: 23975313.
80. Redis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, Zhang X, de Weerd V, Shimizu M, Ling H, Buiga R, Pop V, Irimie A, Fodde R, Bedrosian I, Martens JW, Foekens JA, Berindan-Neagoe I, Calin GA. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget 4(10):1748-62, 2013. e-Pub 2013. PMID: 24077681.
81. Lang JE, Tereffe W, Mitchell MP, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Hortobagyi GN, Babiera GV. Primary tumor extirpation in breast cancer patients who present with Stage IV disease is associated with improved survival. Ann Surg Oncol 20(6):1893-9, 2013. e-Pub 2013. PMID: 23306905.
82. Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast Conserving Therapy. Ann Surg 257(2):173-9, 2013. PMID: 23291658.
83. Yi M, Kuerer HM, Mittendorf EA, Hwang RF, Caudle AS, Bedrosian I, Meric-Bernstam F, Wagner JL, Hunt KK. Impact of the American College of Surgeons Oncology Group Z011 criteria applied to a contemporary patient population. J Am Coll Surg 216(1):105-13, 2013. e-Pub 2012. PMID: 23122536.
84. Kong AL, Tereffe W, Hunt KK, Yi M, Kang T, Weatherspoon K, Mittendorf EA, Bedrosian I, Hwang RF, Babiera GV, Buchholz TA, Meric-Bernstam F. Impact of Internal Mammary Lymph Node Drainage Identified by Preoperative Lymphoscintigraphy on Outcomes in Patients with Stage I to III Breast Cancer. Cancer 118(24):6287-96, 2012. e-Pub 2012. PMID: 22648744.
85. Brewster AM, Bedrosian I, Parker PA, Dong W, Peterson SK, Cantor SB, Crosby M, Shen Y. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118(22):5637-43, 2012. e-Pub 2012. PMID: 22517269.
86. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. Ann Surg Oncol 19(12):3777-84, 2012. e-Pub 2012. PMID: 22622473.
87. Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf EA, Bedrosian I, Hwang RF, Caudle AS, Babiera GV, Akins JS, Kuerer HM, Hunt KK. The Role for Sentinel Lymph Node Dissection after Neoadjuvant Chemotherapy in Patients who present with Node-Positive Breast Cancer. Ann Surg Oncol 19(10):3177-84, 2012. e-Pub 2012. PMID: 22772869.
88. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive Paget Disease of Breast: Clinicopathologic Study of an Under-Recognized Entity in the Breast. Am J Surg Pathol 36(9):1353-8, 2012. PMID: 22895267.
89. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S. Circulating Tumor Cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13(7):688-95, 2012. e-Pub 2012. PMID: 22677156.
90. Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY. Human Nuclease/helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection. Cancer Res 72(11):2802-13, 2012. e-Pub 2012. PMID: 22491672.
91. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 2012. e-Pub 2012. PMID: 22392043.
92. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14(3):R83, 2012. e-Pub 2012. PMID: 22621334.
93. Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera GV, Buchholz TA, Meric-Bernstam F, Bedrosian I. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res 14(3):R82, 2012. e-Pub 2012. PMID: 22621306.
94. Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-Bernstam F, Kuerer HM, Bedrosian I, Crosby MA, Baumann DP, Ross MI, Feig BW, Krishnamurthy S, Hernandez M, Babiera GV. Prospective Evaluation of the Nipple-Areola Complex Sparing Mastectomy for Risk Reduction for Early-Stage Breast Cancer. Ann Surg Oncol 19(4):1137-44, 2012. e-Pub 2011. PMID: 21979111.
95. Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson Prognostic Index for Local-Regional Recurrence after Breast Conserving Therapy in Patients Receiving Neoadjuvant Chemotherapy. Ann Surg Oncol 19(3):901-7, 2012. e-Pub 2011. PMID: 21861223.
96. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK. Evaluation of a Breast Cancer Nomogram for Predicting Risk of Ipsilateral Breast Tumor Recurrences in Patients with Ductal Carcinoma in Situ after Local Excision. J Clin Oncol 30(6):600-7, 2012. e-Pub 2012. PMID: 22253459.
97. Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, Kuerer H, Bedrosian I, Singh B, Lucci A. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer 118(2):342-8, 2012. e-Pub 2011. PMID: 21717428.
98. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Ann Surg Oncol 18(9):2407-12, 2011. e-Pub 2011. PMID: 21327455.
99. Van Leeuwen BL, Rosenkranz KM, Feng LL, Bedrosian I, Hartmann K, Hunt KK, Kuerer HM, Ross M, Singletary SE, Babiera GV, Department of Surgical Oncology, MD Anderson Cancer Center. The effect of undertreatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol 79(3):315-20, 2011. e-Pub 2010. PMID: 20655242.
100. Wagner JL, Warneke CL, Mittendorf EA, Bedrosian I, Babiera GV, Kuerer HM, Hunt KK, Yang W, Sahin AA, Meric-Bernstam F. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg 254(1):119-24, 2011. e-Pub 2011. PMID: 21494124.
101. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg 253(3):572-9, 2011. PMID: 21209588.
102. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics 6(4):129-151, 2010. PMID: 21691416.
103. Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol 17(12):3252-8, 2010. e-Pub 2010. PMID: 20559739.
104. Valero V, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel Lymph Node Dissection is Technically Feasible in Older Breast Cancer Patients. Clin Breast Cancer 10(6):477-82, 2010. e-Pub 2010. PMID: 21147692.
105. Sharma R, Bedrosian I , Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-day locoregional control in patients with T1 or T2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17(11):2899-908, 2010. e-Pub 2010. PMID: 20443145.
106. Kang T, Yi M, Hunt KK, Mittendorf EA, Babiera GV, Kuerer H, Bedrosian I, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to success of sentinel node mapping for breast cancer?. Ann Surg Oncol 17(Suppl 3):343-51, 2010. e-Pub 2010. PMID: 20853047.
107. Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, Bedrosian I, Rourke L, Hunt KK. Trends in and Outcomes from Sentinel Lymph Node Biopsy (SLNB) Alone vs. SLNB with Axillary Lymph Node Dissection for Node-Positive Breast Cancer Patients: Experience from the SEER Database. Ann Surg Oncol Oct. 17, 2010(3):343-51, 2010. e-Pub 2010. PMID: 20853057.
108. Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy. Cancer Prev Res (Phila) 3(8):OF1-9, 2010. e-Pub 2010. PMID: 20647335.
109. Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer 116(11):2543-2548, 2010. PMID: 20336790.
110. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 102(6):401-409, 2010. e-Pub 2010. PMID: 20185801.
111. Fearmonti RM, Gayed IW, Kim E, Bedrosian I, Hunt KK, Meric-Bernstam F, Feig B, Ghonimi E, Warneke C, Babiera GV. Intra-Individual Comparison of Lymphatic Drainage Patterns Using Subareolar and Peritumoral Isotope Injection for Breast Cancer. Ann Surg Oncol 17(1):220-7, 2010. e-Pub 2009. PMID: 19680729.
112. Fearmonti RM, Batista LI, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Eva Singletary S, Babiera GV. False negative rate of sentinel lymph node biopsy in multicentric and multifocal breast cancers may be higher in cases with large additive tumor burden. Breast J 15(6):645-8, 2009. e-Pub 2009. PMID: 19735388.
113. Boughey JC, Goravanchi F, Parris RN, Kee SS, Kowalski AM, Frenzel JC, Bedrosian I, Meric-Bernstam F, Hunt KK, Ames FC, Kuerer HM, Lucci A. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg 198(5):720-5, 2009. e-Pub 2009. PMID: 19427625.
114. Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, Hwang RF, Kuerer HM, Ross MI, Meric-Bernstam F. Sentinel lymph node surgery after Neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 250(4):558-66, 2009. e-Pub 2009. PMID: 19730235.
115. Wagner J, Boughey JC, Garrett B, Babiera G, Kuerer H, Meric-Bernstam F, Singletary E, Hunt KK, Middleton LP, Bedrosian I. Margin Assessment after Neoadjuvant Chemotherapy in Invasive Lobular Cancer. Am J Surg 198(3):387-91, 2009. e-Pub 2009. PMID: 19362281.
116. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M. Cylooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117(1):61-8, 2009. e-Pub 2008. PMID: 18663571.
117. Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I. Neoadjuvant chemotherapy in invasive lobular carcinoma does not improve rates of breast conservation. Ann Surg Oncol 16(6):1606-11, 2009. e-Pub 2009. PMID: 19280264.
118. Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat 115(3):651-9, 2009. e-Pub 2008. PMID: 19107593.
119. Krishnamurthy S, Meric-Bernstam F, Lucci A, Hwang RF, Kuerer HM, Babiera G, Ames FC, Feig BW, Ross MI, Singletary E, Hunt KK, Bedrosian I. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer 115(7):1555-62, 2009. PMID: 19195040.
120. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 115(5):962-71, 2009. e-Pub 2009. PMID: 19172584.
121. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 Status Predicts the Presence of Circulating Tumor Cells in Patients with Operable Breast Cancer. Breast Cancer Res Treat 113(3):501-7, 2009. e-Pub 2008. PMID: 18327638.
122. Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, Ames FC, Lucci A, Hwang RF, Hunt KK. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 196(1):81-7, 2008. e-Pub 2008. PMID: 18436181.
123. Reed VK, Cavalcanti JL, Strom EA, Perkins GH, Oh JL, Tereffe W, Yu TK, Yeung H, Whitman GJ, Bedrosian I, Macapinlac HA, Buchholz TA, Woodward WA. Risk of Subclinical Micrometastatic Disease in the Supraclavicular Nodal Bed According to the Anatomic Distribution in Patients with Advanced Breast Cancer. Int J Radiat Oncol Biol Phys 71(2):435-40, 2008. e-Pub 2007. PMID: 18164831.
124. Rao R, Feng L, Kuerer HM, Singletary SE, Bedrosian I, Hunt KK, Ross MI, Hortobagyi GN, Feig BW, Ames FC, Babiera GV. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 15(6):1696-702, 2008. e-Pub 2008. PMID: 18357493.
125. Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G. Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol 26(15):2482-8, 2008. e-Pub 2008. PMID: 18427152.
126. Boughey JC, Cormier JN, Xing Y, Hunt KK, Meric-Bernstam F, Babiera GV, Ross MI, Kuerer HM, Singletary SE, Bedrosian I. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer 110(11)(11):2542-2550, 2007. PMID: 17932905.
127. Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, Perkins GH, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Akins JS, Hunt KK. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg 194(14)(4):527-531, 2007. PMID: 17826073.
128. Boughey JC, Middleton LP, Harker L, Garrett B, Fornage B, Hunt KK, Babiera GV, Dempsey P, Bedrosian I. Utility of ultrasound and fine needle aspiration biopsy of the axilla in the assessment of invasive lobular carcinoma of the breast. Am J Surg 194(4)(4):450-455, 2007. PMID: 17826054.
129. Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E associated kinase activity predicts response to platinum based chemotherapy. Clin Cancer Res 13(16)(16):4800-4806, 2007. PMID: 17699858.
130. Huang EH, Strom EA, Valero V, Fornage B, Perkins GH, Oh JL, Yu TK, Tereffe W, Woodward WA, Hunt KK, Meric-Bernstam F, Sahin AA, Bedrosian I, Hortobagyi GN, Buchholz TA. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys 67(2):490-496, 2007. PMID: 17236970.
131. Vo TN, Meric-Bernstam F, Yi M, Buchholz TA, Ames FC, Kuerer HM, Bedrosian I, Hunt KK. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 192(4):552-5, 2006. PMID: 16978974.
132. Rosenkranz KM, Bedrosian I, Feng L, Hunt KK, Hartman K, Lucci A, Meric-Bernstam F, Kuerer HM, Singletary ES, Hwang R, Feig B, Ross M, Ames F, Babiera GV. Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg 192(4):541-4, 2006. PMID: 16978971.
133. Boughey JC, Bedrosian I, Meric-Bernstam F, Ross MI, Kuerer HM, Akins JS, Giordano SH, Babiera GV, Ames FC, Hunt KK. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 203(4):475-80, 2006. e-Pub 2006. PMID: 17000390.
134. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 107(7)(7):1440-1447, 2006. PMID: 16955504.
135. Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 244(3):464-70, 2006. PMID: 16926572.
136. Boughey JC, Ross MI, Babiera GV, Bedrosian I, Feig BW, Hwang RF, Kuerer HM, Hunt KK. Sentinel lymph node surgery in locally recurrent breast cancer. Clin Breast Cancer 7(3):248-53, 2006. PMID: 16942642.
137. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle 5(15):1654-61, 2006. e-Pub 2006. PMID: 16861913.
138. Bedrosian I, Giacco G, Pederson L, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA, Vauthey JN, Delclos M, Crane CH, Janjan N, Skibber JM. Outcome after curative resection for locally recurrent rectal cancer. Dis Colon Rectum 49(2):175-82, 2006. PMID: 16392024.
139. Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer 104(3):479-90, 2005. PMID: 15968686.
140. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102(35):12519-24, 2005. e-Pub 2005. PMID: 16116079.
141. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280(15):15148-57, 2005. e-Pub 2005. PMID: 15708847.
142. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 23(15):2648-57, 2004. PMID: 15007381.
143. Bedrosian I, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA, Vauthey JN, Delclos M, Crane C, Janjan N, Skibber JM. Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. J Gastrointest Surg 8(1):56-62; discussion 62-3, 2004. PMID: 14746836.
144. Bedrosian I, Bedi D, Kuerer HM, Fornage BD, Harker L, Ross MI, Ames FC, Krishnamurthy S, Edeiken-Monroe BS, Meric F, Feig BW, Akins J, Singletary SE, Mirza NQ, Hunt KK. Impact of clinicpathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol 10(9):1025-30, 2003. PMID: 14597440.
145. Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 21(20):3826-35, 2003. PMID: 14551301.
146. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 171(5):2251-61, 2003. PMID: 12928369.
147. Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle 2(5):461-6, 2003. PMID: 12963845.
148. Bedrosian I, Mick R, Orel SG, Schnall M, Reynolds C, Spitz FR, Callans LS, Buzby GP, Rosato EF, Fraker DL, Czerniecki BJ. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 98(3):468-73, 2003. PMID: 12879462.
149. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med 347(20):1566-75, 2002. PMID: 12432043.
150. Bedrosian I, Schlencker J, Spitz FR, Orel SG, Fraker DL, Callans LS, Schnall M, Reynolds C, Czerniecki BJ. Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions. Ann Surg Oncol 9(5):457-61, 2002. PMID: 12052756.
151. Bauer TW, Spitz FR, Callans LS, Alavi A, Mick R, Weinstein SP, Bedrosian I, Fraker DL, Bauer TL, Czerniecki BJ. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol 9(2):169-76, 2002. PMID: 11888875.
152. Faries MB, Bedrosian I, Xu S, Koski G, Roros JG, Moise MA, Nguyen HQ, Engels FH, Cohen PA, Czerniecki BJ. Calcium signaling inhibits interleukin-12 production and activates CD83(+) dendritic cells that induce Th2 cell development. Blood 98(8):2489-97, 2001. PMID: 11588047.
153. Wildemore JK, Schuchter L, Mick R, Synnestvedt M, Elenitsas R, Bedrosian I, Czerniecki BJ, Guerry D, Lessin SR, Elder DE, Bucky LP. Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study. Ann Plast Surg 46(5):488-94, 2001. PMID: 11352421.
154. Czerniecki BJ, Bedrosian I, Faries M, Alavi A. Revolutionary impact of lymphoscintigraphy and intraoperative sentinel node mapping in the clinical practice of oncology. Semin Nucl Med 31(2):158-64, 2001. PMID: 11330786.
155. Czerniecki BJ, Cohen PA, Faries M, Xu S, Roros JG, Bedrosian I. Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Crit Rev Immunol 21(1-3):157-78, 2001. PMID: 11642602.
156. Engels FH, Kreisel D, Faries MB, Bedrosian I, Koski GK, Cohen PA, Czerniecki BJ. Calcium ionophore activation of chronic myelogenous leukemia progenitor cells into dendritic cells is mediated by calcineurin phosphatase. Leuk Res 24(10):795-804, 2000. PMID: 10996197.
157. Bedrosian I, Reynolds C, Mick R, Callans LS, Grant CS, Donohue JH, Farley DR, Heller R, Conant E, Orel SG, Lawton T, Fraker DL, Czerniecki BJ. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 88(11):2540-5, 2000. PMID: 10861431.
158. Bedrosian I, Faries MB, Guerry D, Elenitsas R, Schuchter L, Mick R, Spitz FR, Bucky LP, Alavi A, Elder DE, Fraker DL, Czerniecki BJ. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 7(4):262-7, 2000. PMID: 10819365.
159. Bedrosian I, Roros JG, Xu S, Nguyen HQ, Engels F, Faries MB, Koski GK, Cohen PA, Czerniecki BJ. Granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-12 synergize with calcium ionosphere to enhance dendritic cell function. J Immunother 23(3):311-20, 2000. PMID: 10838660.
160. Faries MB, Bedrosian I, Reynolds C, Nguyen HQ, Alavi A, Czerniecki BJ. Active macromolecule uptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status. Ann Surg Oncol 7(2):98-105, 2000. PMID: 10761787.
161. Engels FH, Koski GK, Bedrosian I, Xu S, Luger S, Nowell PC, Cohen PA, Czerniecki BJ. Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. Proc Natl Acad Sci U S A 96(18):10332-7, 1999. PMID: 10468608.
162. Bedrosian I, Scheff AM, Mick R, Callans LS, Bucky LP, Spitz FR, Helsabeck C, Elder DE, Alavi A, Fraker DF, Czerniecki BJ. 99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J Nucl Med 40(7):1143-8, 1999. PMID: 10405134.
163. Czerniecki BJ, Scheff AM, Callans LS, Spitz FR, Bedrosian I, Conant EF, Orel SG, Berlin J, Helsabeck C, Fraker DL, Reynolds C. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 85(5):1098-103, 1999. PMID: 10091794.
164. Clark BD, Bedrosian I , Schindler R, Cominelli F, Cannon JG, Shaw AR, Dinarello CA. Detection of interleukin 1 alpha and 1 beta in rabbit tissues during endotoxemia using sensitive radioimmunoassay. J Appl Physiol (1985) 71(6):2412-8, 1991. PMID: 1778940.
165. Bedrosian I, Sofia RD, Wolff SM, Dinarello CA. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 3(6):568-75, 1991. PMID: 1790304.

Invited Articles

1. Chu C, Bedrosian I. Prophylactic Mastectomy and Breast Reconstruction in Patients at High-Risk for Breast Cancer. Current Breast Cancer Reports, 2020. e-Pub 2020.
2. Wood ME, Rehman HT, Bedrosian I. Importance of family history and indications for genetic testing. Breast J. e-Pub 2019. PMID: 31865627.
3. Carter S, Neuman H, Mamounas EP, Bedrosian I, Moulder S, Montero AJ, Jagsi R. Debating the Optimal Approach to Nodal Management After Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. Am Soc Clin Oncol Educ Book 39:42-48, 2019. e-Pub 2019. PMID: 31099648.
4. Bedrosian I, Parker PA, Brewster AM. Who Should get a contralateral Prophylactic Mastectomy for Breast Cancer. Cancer. e-Pub 2019. PMID: 30645775.
5. Raber B, Bea VJ, Bedrosian I. How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. Magn Reson Imaging Clin N Am 26(2):281-288, 2018. e-Pub 2018. PMID: 29622133.
6. Yao K, Sisco M, Bedrosian I. Contralateral prophylactic mastectomy: current perspectives. Int J Womens Health 8:213-223, 2016. e-Pub 2016. PMID: 27382334.
7. Bevers TB, Bedrosian I, Middleton LP, Scoggins ME. Current multidisciplinary management of high risk lesions. Current Breast Cancer Reports, 2015.
8. Bedrosian I, Nelson H. The paradox of breast MRI: does finding occult disease make a difference. Bull Am Coll Surg 97(10):57-59, 2012. PMID: 23115888.
9. Dominici LS, Mittendorf EA, Yu TK, Bedrosian I. Impact of breast cancer subtypes on local-regional outcomes. Current Breast Cancer Reports, 2010.
10. Bedrosian I. Positron emission tomography in breast cancer management. Am J Oncol Rev 4:50-53, 2005.
11. Bedrosian I, Czerniecki B. Change in surgical management of breast cancer patients based on preoperative MR imaging. Am J Oncol Rev 3:209, 2004. PMID: 12879462.
12. Bedrosian I, Keyomarsi K. Cyclin E and survival in patients with breast cancer. Am J Onc Rev 2:97, 2003. PMID: 12432043.
13. Bedrosian I, Gershenwald JE. Surgical clinical trials in melanoma. Surg Clin North Am 83(2):385-403, 2003. PMID: 12744615.
14. Bedrosian I, Keyomarsi K. Cyclin E in breast cancer. Breast Diseases Quarterly 14:257-258, 2003.
15. Czerniecki BJ, Bedrosian I. Tumor derived peptide vaccines for treatment of melanoma. The Melanoma Letter 15:1-2, 1997.
16. Bedrosian I. The Surgical Management of Newly Diagnosed Breast Cancer Patients who are BRCA 1/2 Mutation Carriers. Breast Journal.

Editorials

1. Wood ME, Cuke M, Bedrosian I. Prevention therapy for breast cancer: How can we do better?. Ann Surg Oncol:1970-1972, 2019. PMID: 30798445.
2. Wood ME, Garber JE, Isaacs C, Masood S, Bedrosian I, Tung N, Chun J, Schnabel FR, Arun BK, International Society of Cancer Risk Assessment and Management. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast J 25(4):575-577, 2019. PMID: 31280501.
3. Bedrosian I. Screening Mammography. Annals of Surgical Oncology, 2018. PMID: 29796872.
4. Bedrosian I, Yao K. Contralateral Prophylactic Mastectomy: Anxiety, Knowledge and Shared Decision Making. Ann Surg Oncol 22(12):3767-3768, 2015. PMID: 25920918.
5. Bedrosian I, Shen Y. Breast conserving therapy or mastectomy: a done deal or one worth returning to?. J Comp Eff Res 4(3):187-189. PMID: 25959556.
6. Bedrosian I, Yao K. Contralateral Prophylactic Mastectomy and Survival: An Ongoing Challenge. Ann Surg Oncol 21(11):3372-4, 2014. PMID: 25047481.
7. Mittendorf EA, Bedrosian I. Breast Cancer Biology: Implication for Local-Regional Therapy. Ann Surg Oncol 9(9):2820-2, 2014. PMID: 24752612.
8. Hwang ES, Bedrosian I. Patterns of Breast Magnetic Resonance Imaging Use An Opportunity for Data-Driven Resource Allocation. JAMA Intern Med 174(1):122, 2014. PMID: 24247170.

Abstracts

1. Raber B, Lin H, Shen Y, Shaitelman S, Bedrosian I. Trends in Regional Nodal Management of Breast Cancer Patients with Low Nodal Burden. Society of Surgical Oncology Annual Cancer Symposium, 2019.
2. Bhardwaj A, Singh H, Rajapakshe K, Gunaratne PH, Coarfa C, Bedrosian I. Repurposing statins for prevention of triple negative breast cancer. AACR 2017, 2017.
3. Bhardwaj A, Tachibana K, Ganesan N, Pan Y, Rajapakshi K, Coarfa C, Gunaratne PH, Bedrosian I. Targeting of miRNA network for prevention of basal-like breast cancer. AACR 2015, 2015.
4. Tachibana K, Bhardwaj A, Ganesan N, Rajapakshe K, Albarracin CT, Gunaratne PH, Coarfa C, Bedrosian I. Annexin A1 overexpression preferentially predicts poor prognosis of basal-like breast cancer patients by activating mTOR-S6 signaling. AACR, 2015.
5. Colfry A, Lin H, Shen Y, Kuerer HM, Shailtelman S, Babiera G, Bedrosian I. Factors Associated with DCIS diagnosis: A Population based review of the National Cancer Database. Annual Cancer Symposium of the Society of Surgical Oncology, 2015.
6. Yao K, Rosenberg S, Belkora J, Sisco M, Novotny P, Liederbach E, Sepucha K, Tilburt J, Rabbitt S, Bedrosian I. Knowledge deficits and concerns about Contralateral Breast Cancer Risk: A prospective study. Society of Surgical Oncology 68th Annual Cancer Symposium, 2015.
7. Lin HY, Babiera G, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno N, Shen Y. Factors influencing treatment of inflammatory Breast Cancer. Breast Cancer Symposium, 2015.
8. Parker C, Lin H, Shen Y, Li L, Lautner M, Kuerer HM, Shaitelman SF, Babiera G, Bedrosian I. Effect of hormone receptor status and local treatment on overall survival for early-stage breast cancer. ASCO Breast Cancer Symposium 2014, 2014.
9. Parker PA, Peterson SK, Bedrosian I , Crosby MA, Shen Y, Black S, Babiera G, Kuerer H, Ying J, Cantor SB, Brewster AM. Psychosocial Predictors and Communication Process Associated with Contralateral Prophylactic Mastectomy (CPM). Annals of Behavioral Medicine 47. e-Pub 2014.
10. Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I. Risk of breast cancer in women observed after core biopsy diagnosis of atypical ductal hyperplasia. SSO 2014, 2014.
11. Lautner M, Parker C, Lin H, Shen Y, Kuerer HM, Babiera G, Bedrosian I. National Trends in Mastectomy Rates from 1998 to 2010. SSO 2014, 2014.
12. Urnovitz HB, Beck JB, Schutz E, Singh G, Mitchell WM, Black DM, Babiera G, Bedrosian I, Kuerer HM, Mills GB, Meric-Bernstam F. Modulation of breast cancer cell-free DNA with surgical resection, 2013.
13. Shen MC, Bloom E, Shaitelman SF, Wei C, Haynes AB, Mittendorf EA, Kuerer HM, Bedrosian I, Hwang RF, Hunt KK, Tereffe W, Strom E, Babiera GV. Comparison of infectious complications between breast conserving therapy with catheter-based accelerated partial irradiation and whole breast irradiation. San Antonio Breast Cancer Symposium, 2013.
14. Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I. Suppression of Akt-m TOR pathway-a novel component of oncogene induced DNA damage response (DDR) barrier in breast. AACR, 2013.
15. Bloom E, Gifford KA, Kirsner S, Kisling KD, Nelson CL, Mason BE, Bejarano M, Hoover S, Hunt K, Bedrosian I, Babiera G. The Importance of Multidisciplinary Collaboration Between Surgeon and Radiation Oncologist for Optimal Placement of Single-Entry Brachytherapy Catheters for Accelerated Partial Breast Irradiation. Annals of Surgical Oncology(19):28, 2012.
16. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Lucci A, Bedrosian I, Kuerer HM, Hunt K, Huo L, Babiera G. Primary Tumor Resection as a component of multimodality treatment may improve survival and local disease control in Stage IV Inflammatory Breast Cancer. 2012 ASCO Meeting, 2012.
17. Bhardwaj A, Ganesan N, Molkentine D, Raju U, Bedrosian I. miR-34 a as a radio sensitizer of triple negative breast cancer. AACR, 2012.
18. Allen LR, Xing Y, Abedel-Rahman S, Babiera G, Cormier J, Hunt KK, Lucci A, Meric-Bernstam F, Mittendorf EA, Ross M, Le-Petross H, Whitman G, Bedrosian I. A Cost analysis of MRI Utilization in Invasive Lobular Carcinoma. SSO, 2012.
19. Gullett AE, Sneige N, Prieto VG, Kelly CM, Bassett RL, Resetkova E, Duan Z, Li Y, Rosen D, Wu Y, Huo L, Klein K, Bedrosian I, Arun B, Hunt K, Albarracin CT. Pathological and Clinical Characteristics of Mammary Paget Disease: 25-Year Experience from a Major Tertiary Referral Center. 2012 United States & Canadian Academy of Pathology Annual Meeting, 2012.
20. Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera G, Yi M, Ross MI, Hortobagyi GN, Hunt K. Impact of chemotherapy timing on local-regional failures in patients with breast cancer undergoing breast-conserving therapy. J Clin Oncol 29(27_suppl):82, 2011.
21. Bedrosian I, Abdel-Rahman S, Whitman GJ, Cormier JN, Krishnamurthy S, Meric-Bernstam F, Babiera GV, Hunt KK, Hwang RF, Lucci A, Feig BW, Ross MI, Mittendorf EA, Kuerer HM, Le-Petross H. Prospective Study to Evaluate Surgical Impact and Cost of Routine Preoperative Breast MRI in Women with Invasive Lobular Carcinoma. Society of Surgical Oncology 64 Annual Cancer Symposium, March 2-5, 2011, San Antonio, TX, 2011.
22. Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, Kuerer HM, Bedrosian I, Lucci A. Bone marrow stromal-derived growth factor-1 and interleukin-8 levels are increased in stage I-III breast cancer patients with disseminated tumor cells. 2011 ASCO Annual Meeting, 2011.
23. Bhattacharyya A, Krishnamurthy S, Lodhi A, Hall C, Anderson A, Kuerer HM, Bedrosian I, Jackson S, Singh B, Lucci A. HER2 amplification in primary tumor predicts presence of circulating tumor cells in inflammatory breast cancer. 2011 ASCO Annual Meeting, 2011.
24. Brewster AM, Parker PA, Bedrosian I, Dong W, Peterson SK, Cantor SB, Crosby M, Shen Y. Association between contralateral prophylactic mastectomy and breast cancer. 2011 ASCO Annual Meeting, 2011.
25. Gullett AE, Prieto VG, Lopez A, Klein K, Arun B, Bedrosian I, Resetkova E, Wu Y, Sneige N, Albarracin CT. Type of Mammary Paget Disease is associated with Disease Free Survival. United States and Canadian Academy of Pathology, 2010.
26. Tanaka M, Bedrosian I, Chang GJ, You YN, Li D, Rodriguez-Bigas MA, Skibber JM, Abbruzzese JL, Eng C. Single nucleotide polymorphisms (SNP's) of hypoxia-related genes correlate with pathological complete response following neoadjuvant chemoradiation for locally advanced rectal cancer. American Society of Clinical Oncology Annual Meeting 2010, 2010.
27. Dominici LS, Mittendorf EA, Liu J, Kuerer JM, Hunt KK, Brewster A, Babiera GV, Meric-Bernstam F, Yu TK, Bedrosian I. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. ASCO Breast Cancer Symposium, Oct 8-10, 2009 San Francisco, CA, 2009.
28. Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A Phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. ASCO Breast Cancer Symposium, Oct 8-10 2009, San Francisco, CA, 2009.
29. Bedrosian I, Hao Q, Ding L, Rodriguez-Bigas M, Skibber J, Chang G, Story M. Genomic profiling of pathologic complete response in locally advanced rectal cancer. ACS, 94th Annual Clinical Congress, Oct 11-15, 2009 Chicago, IL, 2009.
30. Bedrosian I. Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients. ASCO 2008 Breast Cancer Symposium 9/2008, 2008.
31. Mosalpuria K, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Cristofanilli M, Lucci A. Correlation of COX-2 expression with Stage I-III Triple Receptor Negative Breast Cancer. Academic Surgical Congress, February 12-15, 2008, Huntington Beach, CA, 2008.
32. Wagner, Boughey, Garrett, Babiera, Kuerer, Meric-Bernstam, Singletary, Hunt, Middleton, Bedrosian I. Margin Assessment after Neoadjuvant Chemotherapy in Invasive Lobular Cancer. ASCO Breast Cancer Symposium, September 5-7 2008, Washington DC, 2008.
33. Boughey JC, Ross MI, Kuerer HM, Yi M, Akins JS, Giordano SH, Babiera GV, Ames FC, Lucci A, Singletary SE, Meric-Bernstam F, Bedrosian I, Hunt KK. Comparative analysis of SLN surgery in male and female breast cancer patients. American Society of Clinical Oncology Breast, Sept 7 - 8, 2007, San Francisco, CA, 2007.
34. Yi M, Hunt KK, Bedrosian I, Meric-Bernstam F, Babiera GV, Akins J, Hwang R, Kuerer HM, Lucci A, Ross MI. Sentinel lymph node biopsy in patients with multicentric invasive breast cancer. American Society of Clinical Oncology, June 1 - 5, 2007, Chicago, IL, 2007.
35. Boughey JC, Cormier JN, Xing Y, Meric-Bernstam F, Ross MI, Babiera GV, Ames FC, Hunt KK, Bedrosian I. Routine use of sentinel lymph node surgery in patients undergoing prophylactic mastectomy: a decision analysis model. American Society of Clinical Oncology, June 1 - 5, 2007, Chicago, IL, 2007.
36. Fearmonti RM, Batista LI, Meric-Bernstam F, Hunt KK, Bedrosian I, Kuerer HM, Singletary SE, Babiera GV. Margin width correlates with residual disease at re-excision for ductal carcinoma in situ (DCIS) of the breast. American Society of Clinical Oncology, June 1 - 5, 2007, Chicago, IL, 2007.
37. Lang JE, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi G, Babiera GV. Primary tumor extirpation in breast cancer patients who present with stage IV disease improves overall survival. American Society of Clinical Oncology, June 1 - 5, 2007, Chicago, IL, 2007.
38. Boughey JC, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Kuerer HM, Lucci A, Hunt KK, Bedrosian I. Neoadjuvant chemotherapy in invasive lobular carcinoma does not improve rates of breast conservation. American Society of Clinical Oncology, June 1 - 5, 2007, Chicago, IL, 2007.
39. Yi M, Hunt KK, Krishnamurthy S, Kuerer HM, Bedrosian I, Ames FC, Lucci A, Meric-Bernstam F, Ross MI. The significance of primary tumor characteristics in predicting positive sentinel lymph nodes in ductal carcinoma in situ or microinvasive breast cancer. American Society of Breast Surgeons, May 2 - 6, 2007, Phoenix, AZ, 2007.
40. Thao V, Yang Z, Meric-Bernstam F, Symmans FW, Buchholz TA, Ames FC, Kuerer HM, Bedrosian I, Hunt KK. Long-term outcomes for mucinous, medullary, and tubular carcinomas treated with breast conservation therapy. American Society of Breast Surgeons, May 2 - 6, 2007, Phoenix, AZ, 2007.
41. Boughey JC, Middleton L, Harker L, Garrett B, Fornage B, Hunt KK, Babiera GV, Dempsey PJ, Bedrosian I. Ultrasound and fine needle aspiration for preoperative nodal staging of patients with invasive lobular carcinoma of the breast. American Society of Breast Surgeons, May 2 - 6, 2007, Phoenix, AZ, 2007.
42. Frearmonti RM, Gayed IW, Kim E, Warneke C, Bedrosian I, Hunt KK, Ghonimi E, Meric-Bernstam F, Babiera GV. In vivo comparison of lymphatic drainage patterns of subareolar and peritumoral isotope injection for breast cancer. The Society of Surgical Oncology, March 15 - 18, 2007, Washington, DC, 2007.
43. Boughey JC, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Kuerer HM, Lucci A, Hunt KK, Bedrosian I. Neoadjuvant chemotherapy in invasive lobular carcinoma does not improve rates of breast conservation. ASCO Breast Cancer Symposium September 7-8 2007, San Francisco, CA, 2007.
44. Rosenkranz KM, Hatmann K, Ghonimi E, Kuerer HM, Singletary SE, Hunt KK, Meric-Bernstam F, Lucci A, Hwang R, Bedrosian I , Feig B, Ross MI, Ames F, Babiera GV. Breast cancer in the very elderly; treatment patterns in a tertiary cancer center. American Society of Breast Surgeons, Dec 13 - 15, 2006, San Antonio, TX, 2006.
45. Boughey JC, Cormier JN, MPH, Xing Y, Meric-Bernstam F, Ross MI, Babiera G, Ames FC, Hunt KK, Bedrosian I. Routine use of sentinel lymph node surgery in patients undergoing prophylactic mastectomy: A decision analysis model. American Society of Clinical Oncology 42nd Annual Meeting, June 2 - 6, 2006, Atlanta, GA, 2006.
46. Bedi DG, Krishnamurthy R, Krishnamurthy S, Edeiken B, Le-Petross H, Hunt K, Feig BW, Singletary SE, Ross MI, Ames FC, Bedrosian I, Meric F, Kuerer HM, Fornage BD. Cortical morphology of axillary lymph nodes as a predictor of metastatic disease in breast cancer: an in-vitro ultrasound study. American Roentgen Ray Society 106th Annual Meeting, May 2006, Vancouver, BC, Canada, 2006.
47. Boughey JC, Peintinger F, Pusztai L, Meric-Bernstam F, Perry A, Hunt KK, Singletary SE, Ames FC, Ross MI, Lucci A, Babiera GV, Bedrosian I , Hwang R, Buzdar AU, Kuerer HM. Extent and number of surgical procedures in 509 patients treated with preoperative versus postoperative chemotherapy on randomized clinical trials for breast cancer. American Surgical Association, April 20 - 22, 2006, Boston, MA, 2006.
48. Bedrosian I, Lee C, Munsell M, Lu K, Keyomarsi K. Cyclin E deregulation as a marker of response to chemotherapy and survival in ovarian cancer. American Association of Cancer Research, April 1 - 5, 2006, Washington DC, 2006.
49. Boughey JC, Hunt KK, Ames FC, Babiera GV, Bedrosian I, Feig BW, Hwang RF, Kuerer HM, Singletary SE, Ross MI. Sentinel Lymph Node Surgery in Locally Recurrent Breast Cancer. The Society of Surgical Oncology 59th Annual Cancer Symposium, March 23 - 26, 2006, San Diego, CA, 2006.
50. Boughey JC, Hunt KK, Ames FC, Babiera GV, Bedrosian I, Feig BW, Hwang RF, Kuerer HM, Singletary SE, Ross MI. Sentinel lymph node surgery in locally recurrent breast cancer. The Society of Surgical Oncology, Mar 2 - 5, 2005, Atlanta, GA, 2005.
51. Bedrosian I, Keyomarsi K. Cyclin E kinase activity is dependent on p53 status of colon tumor cells. American Association of Cancer Research, May 27 - 31, 2004; Orlando, FL, 2004.
52. Bedrosian I, Giacco G, Pederson L, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA, Vauthey JN, Skibber JM. Outcome after Curative Resection for Locally Recurrent Rectal Cancer. Society of Surgical Oncology, March 17 - 21, 2004; New York, New York, 2004.
53. Bedrosian I, Zhang N, Keyomarsi K. Ovarian cancer cells circumvent G1 arrest through deregulation of cyclin E. American Association of Cancer Research, July 11 - 14, 2003; Washington D.C, 2003.
54. Bedrosian I, Ross MI, Prieto VG, Johnson M, Lee JE, Mansfield PF, Gershenwald JE. Impact of Melanoma Sentinel Lymph Node (SLN) Tumor Burden on Incidence and Extent of Stage IV disease. American Society of Clinical Oncology, May 18 - 21, 2002; Orlando, Florida, 2002.
55. Bedrosian I, Bedi D, Kuerer H, Fornage B, Harker L, Ross M, Ames F, Krishnamurthy S, Edeiken-Monroe B, Singletary SE, Mirza N, Hunt KK. Impact of Clinicopathologic Factors on Ultrasound Detection of Axillary Nodal Metastasis in Patients with Early Stage Breast Cancer. Society of Surgical Oncology, March 14 - 17, 2002; Denver, Colorado, 2002.
56. Bedrosian I, Schlenker J, Mick R, Orel SG, Schnall M, Reynolds C, Spitz FR, Callans LS, Buzby GP, Rosato EF, Fraker DL, Czerneicki BJ. Change in Surgical Management of Breast Cancer Patients based on Preoperative Breast MRI. American Society of Clinical Oncology. American Society of Clinical Oncology, May 20 - 23, 2001, 2001.
57. Bedrosian I, Spitz FR, Schlenker J, Orel SG, Schnall M, Reynolds C, Callans LS, Fraker DL, Czerneicki BJ. Breast MRI is a Sensitive Technique for Detection of Multifocal Disease. Society of Surgical Oncology, March 16 - 19, 2000; New Orleans, Louisiana, 2000.
58. Bedrosian I, Spitz F, Callans LS, Bucky L, Guerry D, Elder DE, Fraker DL, Czerniecki BJ. Presence of VGP in thin melanoma identifies patients at risk for nodal metastasis. Society of Surgical Oncology, March 4 - 7, 1999; Orlando, FL, 1999.
59. Bedrosian I, Engels FHC, Faries MB, Xu S, Czerneicki BJ. Primary in vitro sensitization of CD4+T cells using dendritic cells pulsed with tumor antigens. American Association of Cancer Research, April 8, 1999; Philadelphia, PA, 1999.
60. Bedrosian I, Scheff AM, Callans LS, Spitz FR, Conant E, Orel SG, Berlin J, Helsabeck C, Fraker DL, Reynolds C, Czerniecki BJ. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel node biopsy in patients with breast cancer. 21st Annual San Antonio Breast Cancer Symposium, December 12 - 15, 1998; San Antonio, TX, 1998.
61. Bedrosian I, Callans L, Buzby G, Orel S, Schnall M, Reynolds C, Fraker DL, Czerniecki BJ. Potential Role of Breast MRI in the Initial Management of Breast Cancer Patients. Society of Surgical Oncology, March 25 - 28, 1998; San Diego, CA, 1998.

Book Chapters

1. Fayanju OM, Garvey P, Karuturi M, Hunt KK, Bedrosian I. Surgical Procedures for Advanced Local and Regional Malignancies of the Breast. In: The Breast. 5th. Elsevier: St. Louis, 778-801.e4, 2018.
2. Lautner MA, Parker CC, Bedrosian I. Breast Cancer Subtypes Identified by Gene Expression Profiles and Molecular Markers. In: A textbook of Surgical Oncology, 2018.
3. Le-Petross H, Cristofanili M, Stafford J, Bedrosian I, Garvey P. Breast Cancer. In: Oncologic Imaging-A Multidisciplinary Approach. Elsevier: Philadelphia, PA, 2012.
4. Bedrosian I. The Concept of Prophylactic. In: Kuerer's Breast Surgical Oncology, 2009.
5. Bevers T, Bedrosian I. Advanced Therapy in Surgical Oncology. In: Chapter 72: Prevention: Prophylactic Mastectomy and Chemoprevention. BC Decker, Inc: Hamilton, Ontario, Canada, 2007.
6. Bedrosian I, Lambert L, Pollock RE. Long term consequences of cancer surgery. In: Internal Medicine Care of Cancer Patients. BC Decker, 2007.
7. Boughey JC, Bedrosian I. Sentinel lymph node surgery during prophylactic mastectomy (Methodology). In: Methods of cancer, diagnosis, treatment, and prognosis. Springer, 2006.
8. Bedrosian I, Middleton L. Tubular, Mucinous and Medullary Carcinoma. In Press. In: Advanced Therapy of Breast Disease. 3rd. BC Decker: Ontario, Canada, 2005.
9. Dowdy SC, Stefanek M, Hartmann LC, Lu K, Bedrosian I. Surgical Risk Reduction: Prophylactic Mastectomy and Prophylactic Bilateral Salpingo-oophorectomy. In: Advanced Therapy of Breast Disease. 3rd. Peoples Medical Publishing House: USA, 2004.
10. Bedrosian I, Bland KI, Hunt KK. General Considerations for Follow-up. In: The Breast: Comprehensive Management of Benign and Malignant Disorders. W.B. Saunders: Philadelphia, 2004.
11. Bedrosian I, Czerniecki C. Tumor Biology. In: The Surgical Review. Lippincott, Williams and Wilkins: Philadelphia, 2000.

Letters to the Editor

1. Keyomarsi K, Tucker SL, Bedrosian I. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 9: 152, 2003.